What is the treatment for Pasteurella multocida infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Pasteurella multocida Infections

For Pasteurella multocida infections, doxycycline (100 mg twice daily) is recommended as first-line therapy due to its excellent activity against the organism, with amoxicillin-clavulanate (875/125 mg twice daily) as an effective alternative. 1

First-Line Treatment Options

Oral Therapy

  • Doxycycline: 100 mg twice daily 1

    • Excellent activity against P. multocida
    • FDA-approved for P. multocida infections 2
    • Particularly useful for respiratory infections 3
  • Amoxicillin-clavulanate: 875/125 mg twice daily 1

    • Effective against P. multocida and other common co-infecting organisms
    • Good choice for polymicrobial infections (common in animal bites)
  • Penicillin/Amoxicillin: 500 mg four times daily (penicillin) or 500 mg three times daily (amoxicillin) 1, 4

    • Traditional first-line therapy
    • Highly effective against P. multocida
    • Limited coverage for other potential pathogens

Intravenous Therapy (for severe infections)

  • Ampicillin-sulbactam: 1.5-3.0 g every 6-8 hours 1
  • Piperacillin-tazobactam: 3.37 g every 6-8 hours 1
  • Carbapenems (imipenem, meropenem, ertapenem) 1

Alternative Options (for penicillin-allergic patients)

  • Fluoroquinolones:

    • Ciprofloxacin: 500-750 mg twice daily 1
    • Levofloxacin: 750 mg daily 1
    • Moxifloxacin: 400 mg daily (monotherapy; also covers anaerobes) 1
  • Second/Third-generation cephalosporins:

    • Cefuroxime: 500 mg twice daily (oral) or 1 g every 12 hours (IV) 1
    • Ceftriaxone: 1 g every 12 hours (IV) 1
    • Cefotaxime: 1-2 g every 6-8 hours (IV) 1
  • Trimethoprim-sulfamethoxazole: 160-800 mg twice daily 1, 5

    • Good activity against aerobes but poor against anaerobes

Treatment Algorithm

  1. Assess infection severity:

    • Localized infection: Oral therapy
    • Systemic infection, immunocompromised host, or deep tissue involvement: IV therapy
  2. Consider infection source:

    • Animal bite-related: Cover for polymicrobial infection with amoxicillin-clavulanate
    • Respiratory infection: Doxycycline or penicillin
    • Bacteremia: IV therapy with ampicillin-sulbactam or piperacillin-tazobactam
  3. Evaluate patient factors:

    • Penicillin allergy: Use doxycycline, fluoroquinolones, or trimethoprim-sulfamethoxazole
    • Renal/hepatic impairment: Adjust dosing accordingly

Duration of Therapy

  • Uncomplicated soft tissue infections: 5-7 days
  • Respiratory infections: 7-14 days
  • Bacteremia: 10-14 days
  • Osteomyelitis or septic arthritis: 4-6 weeks 1

Important Clinical Considerations

  • P. multocida infections typically develop rapidly after animal exposure (especially cat or dog bites) with marked inflammation within 24 hours 6, 4
  • Infections can progress from localized cellulitis to invasive disease including osteomyelitis, septic arthritis, and bacteremia 4
  • Hand wounds are particularly concerning and require prompt treatment 4
  • Clindamycin should be avoided as it has poor activity against P. multocida 1
  • First-generation cephalosporins (cephalexin), macrolides (erythromycin), and penicillinase-resistant penicillins (dicloxacillin) have poor activity against P. multocida 1

Adjunctive Measures

  • Thorough wound cleaning and irrigation for bite-related infections
  • Surgical debridement may be necessary for abscesses or necrotic tissue
  • Tetanus prophylaxis should be considered if vaccination is not current 1
  • Wounds should not be closed if infected 1

By following this treatment approach and selecting appropriate antimicrobial therapy based on infection severity and patient factors, P. multocida infections can be effectively managed with excellent outcomes.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pasteurella multocida pneumonia.

Seminars in respiratory infections, 1997

Research

Pasteurella Multocida Infection in Humans.

Pathogens (Basel, Switzerland), 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.